Valuation : Futura Medical plc

Market Cap 1.62M 2.19M 1.88M 1.77M 3.02M 206M 3.03M 20.91M 8.11M 106M 8.21M 8.03M 341M P/E 2024
77.2x
P/E 2025 -0.4x
Enterprise Value -1.79M -2.41M -2.08M -1.95M -3.34M -228M -3.35M -23.1M -8.96M -117M -9.07M -8.87M -377M EV / Sales 2024
6,428,637x
EV / Sales 2025 1,815,433x
Free-Float
87.2%
Yield 2024 *
-
Yield 2025 -
1 day+4.00%
1 week-13.33%
Current month+4.00%
1 month-27.78%
3 months-91.33%
6 months-78.33%
Current year-81.09%
1 week 0
Extreme 0.0025
0
1 month 0
Extreme 0.0025
0.01
Current year 0
Extreme 0.0014
0.04
1 year 0
Extreme 0.0013
0.18
3 years 0
Extreme 0.0013
0.72
5 years 0
Extreme 0.0013
2.7
10 years 0
Extreme 0.0013
2.7
Manager TitleAgeSince
Chief Executive Officer 56 2025-08-07
Director of Finance/CFO 46 2018-02-19
Chief Tech/Sci/R&D Officer 74 2016-11-15
Director TitleAgeSince
Director/Board Member 74 2016-03-31
Director/Board Member 46 2018-02-19
Chairman 69 -
Change 5-day change 1-year change 3-year change Capi.($)
+4.00%-13.33% - - 2.19M
-1.79%-2.27%+50.90%+89.03% 67.98B
-2.06%-0.18%+41.53%+88.17% 64.94B
-0.31%+6.54%-11.39%+457.82% 27.58B
-3.00%-2.90%+39.40%+9.41% 25.74B
+0.86%+1.65%+0.25%-14.78% 26.06B
-1.46%+0.42%+24.07%-18.70% 20.09B
-2.96%-15.21%+210.71%+370.84% 17.16B
-1.49%-4.88%-0.41%+530.26% 14.92B
-0.20%+8.37%+57.87%+159.50% 14.62B
Average -0.84%+0.26%+45.88%+185.73% 31.01B
Weighted average by Cap. -1.52%+0.18%+42.29%+145.08%

Financials

2024 2025
Net sales 13.93 18.83 16.2 15.24 26.05 1.78K 26.12 180.14 69.9 912.15 70.71 69.17 2.94K 1.7 2.29 1.97 1.86 3.17 216.6 3.18 21.95 8.52 111.13 8.61 8.43 358.01
Net income 1.29M 1.75M 1.5M 1.42M 2.42M 165M 2.43M 16.73M 6.49M 84.69M 6.57M 6.42M 273M -9.07M -12.26M -10.55M -9.93M -16.97M -1.16B -17.01M -117M -45.53M -594M -46.06M -45.05M -1.91B
Net Debt -6.6M -8.92M -7.67M -7.22M -12.34M -842M -12.37M -85.33M -33.11M -432M -33.49M -32.76M -1.39B -3.4M -4.6M -3.96M -3.72M -6.36M -434M -6.38M -44M -17.07M -223M -17.27M -16.89M -718M
Logo Futura Medical plc
Futura Medical plc is a consumer healthcare company that specializes in the development and global commercialization of sexual health products. The Company is a developer of sexual health products, including the lead product, Eroxon, and two products in development, including WSD4000 and Eroxon Intense. Eroxon is a clear gel used for the treatment of erectile dysfunction (ED) available over the counter and without prescription and addresses significant unmet needs in the ED market. Eroxon Intense provides a potential range extension of the Eroxon product and acts as an additional treatment option for men who have ED. WSD4000 is a topical treatment designed for sexual dysfunction in women. The Company has distribution partners in place in a number of major consumer markets, including Haleon in the United States, and Cooper Consumer Health in Europe.
Employees
13
Date Price Change Volume
26-09-04 US$0.002600 +4.00% 3,988
26-08-31 US$0.002500 -16.67% 107,990
26-08-28 US$0.003000 -34.78% 7,964
26-08-27 US$0.004600 +53.33% 10,000

Annual profits - Rate of surprise